



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)

### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)
- [Endnotes](#)

### Policy Number: 797

BCBSA Reference Number: 2.04.141

NCD/LCD:

- Local Coverage Determination (LCD): Non-covered Services (L33629)
- Local Coverage Determination (LCD): MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (L37699)

### Related Policies

Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #[336](#)

### Policy<sup>1</sup>

## Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered **MEDICALLY NECESSARY** when the following criteria have been met:

#### Diagnosis:

- When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND
- When prior results for ALL of the following tests are not available:
  - EGFR single nucleotide variants (SNVs) and insertions and deletions (indels)
  - ALK and ROS1 rearrangements
  - PDL1 expression.

#### Progression:

- Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR
- For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered.

Other plasma-based CGP tests are considered [INVESTIGATIONAL](#).

CGP and the use of circulating tumor DNA is considered [INVESTIGATIONAL](#) for all other indications.

The use of circulating tumor cells is considered [INVESTIGATIONAL](#) for all indications.

## Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Medical necessity criteria and coding guidance for **Medicare Advantage members living in Massachusetts** can be found through the link(s) below.

### [Local Coverage Determination \(LCDs\) for Palmetto GBA on Molecular Diagnostic Tests](#)

Guardant360® plasma-based comprehensive somatic genomic profiling test (hereafter called CGP) for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is a covered service.

Local Coverage Determination (LCD): MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (L37699)

The use of circulating tumor cells is not a covered service.

### [Local Coverage Determination \(LCD\): Non-covered Services \(L33629\)](#)

**Note:** To review the specific LCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

For medical necessity criteria and coding guidance for **Medicare Advantage members living outside of Massachusetts**, please see the Centers for Medicare and Medicaid Services website at <https://www.cms.gov> for information regarding your specific jurisdiction.

## Prior Authorization Information

### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
<b>Commercial Managed Care (HMO and POS)</b>	The requirements of BCBSMA Genetic Testing Management Program require prior authorization via AIM Specialty Health. These requirements are member-specific:
<b>Commercial PPO and Indemnity</b>	Please verify member eligibility and requirements through <b>Online Services</b> by logging onto <a href="#">Provider Central</a> . Refer to our <a href="#">Quick Tip</a> for an overview of pre-certification and prior authorization requirements.  Ordering clinicians should request prior authorization from <a href="#">AIM Specialty Health</a> . <a href="#">AIM's ProviderPortal</a> <sup>SM</sup> registration is required or call 1-866-745-1783 (when applicable).
<b>Medicare HMO Blue Medicare PPO Blue</b>	Prior authorization through AIM Specialty Health is <b>not</b> required for Medicare Advantage products. Please see the appropriate National Coverage

	Determination (NCD) or Local Coverage Determination (LCD) through the <a href="#">CMS website</a> for specific genetic testing guidelines.
--	--

**CPT Codes / HCPCS Codes / ICD Codes**

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

**The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:**

**CPT Codes**

<b>CPT codes:</b>	<b>Code Description</b>
81445	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed
81450	Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed
81455	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed

**Description**

Liquid biopsy refers to analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) as a method of noninvasively characterizing tumors and tumor genome from the peripheral blood.

**Circulating Tumor DNA**

Normal and tumor cells release small fragments of DNA into the blood, which is referred to as cell-free DNA (cfDNA). cfDNA from nonmalignant cells is released by apoptosis. Most cell-free tumor DNA is derived from apoptotic and/or necrotic tumor cells, either from the primary tumor, metastases, or CTCs. Unlike apoptosis, necrosis is considered a pathologic process, and generates larger DNA fragments due to an incomplete and random digestion of genomic DNA. The length or integrity of the circulating DNA can potentially distinguish between apoptotic and necrotic origin. ctDNA can be used for genomic characterization of the tumor.

**Circulating Tumor Cells**

Intact CTCs are released from a primary tumor and/or a metastatic site into the bloodstream. The half-life of a CTC in the bloodstream is short (1-2 hours), and CTCs are cleared through extravasation into secondary organs. Most assays detect CTCs through the use of surface epithelial markers such as EpCAM and cytokeratins. The primary reason for in detecting CTCs is prognostic, through quantification of circulating levels.

---

## Technologies for Detecting ctDNA and CTCs

Detection of ctDNA is challenging because ctDNA is diluted by nonmalignant circulating DNA and usually represents a small fraction (<1%) of total cfDNA. Therefore, more sensitive methods than the standard sequencing approaches (eg, Sanger sequencing) are needed.

Highly sensitive and specific methods have been developed to detect ctDNA, for both single-nucleotide mutations (eg BEAMing [which combines emulsion polymerase chain reaction [PCR] with magnetic beads and flow cytometry] and digital PCR) and copy-number changes. Digital genomic technologies allow for enumeration of rare mutant variants in complex mixtures of DNA.

Approaches to detecting ctDNA can be considered targeted, which includes the analysis of known genetic mutations from the primary tumor in a small set of frequently occurring driver mutations, which can impact therapy decisions (eg, *EGFR* and *ALK* in non-small-cell lung cancer), or untargeted without knowledge of specific mutations present in the primary tumor, and include array comparative genomic hybridization, next-generation sequencing, and whole exome and genome sequencing.

CTC assays usually start with an enrichment step that increases the concentration of CTCs, either on the basis of biologic properties (expression of protein markers) or physical properties (size, density, electric charge). CTCs can then be detected using immunologic, molecular, or functional assays.

## Summary

Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in peripheral blood, referred to as “liquid biopsy,” potentially offer a noninvasive alternative to tissue biopsy for therapeutic decisions and clinical prognosis in patients with cancer.

For individuals who have cancer who receive molecular characterization of tumor using ctDNA, the evidence includes case series and systematic reviews of these case series. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, morbid events, and medication use. Ultrasensitive methods to detect mutations from ctDNA have been developed, but there is limited evidence on the analytic validity of these methods. There is a need for further optimization and standardization of testing methods. Clinical validity consists of case series that report correlations between mutations detected in ctDNA with mutations detected in tumor tissue. Results have shown variable results for clinical sensitivity. Although some reports have suggested that clinical sensitivity may be high, this finding has not been consistent. Published studies have consistently reported high clinical specificity; however, most study populations are small and heterogeneous, and it is not known to what degree mutations detected by ctDNA are representative of the primary tumor. Published studies reporting clinical outcomes and/or clinical utility are lacking. However, specifically for ctDNA in non-small cell lung cancer (NSCLC), the evidence supports improved health outcomes at tumor progression and at diagnosis if tissue sample is unobtainable.

For individuals who have cancer or are at high risk of developing cancer who receive identification and quantification of CTCs, the evidence includes case series and meta-analyses of these case series. Relevant outcomes are overall survival, disease-specific survival, and test accuracy and test validity.

Published data on analytic validity are lacking. Most of the literature consists of reports of levels of CTCs and cancer prognosis, and have shown a correlation with survival in certain cancer types. However, the cutoff levels that should be used to signal a change in patient management are unknown, and there are no studies showing clinical utility and improved patient outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes. If a separate evidence review exists, then conclusions reached there supersede conclusions in this review.

## Policy History

Date	Action
6/2020	Policy reactivated. Prior authorization clarified. Prior authorization is required through AIM Specialty Health. Effective 6/8/2020.

8/2018	Local Coverage Determination (LCD): MoIDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (L37699) added. Effective 8/27/2018.
10/2017	Clarified coding information.
9/1/2017	New medically necessary indications described. Clarified coding information. Effective 9/1/2017.
10/2016	New medical policy describing investigational indications. Effective 10/1/2016.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Alix-Panabieres C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov*. May 2016;6(5):479-491. PMID 26969689
2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat Med*. May 2014;20(5):548-554. PMID 24705333
3. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. Feb 19 2014;6(224):224ra224. PMID 24553385
4. Mao C, Yuan JQ, Yang ZY, et al. Blood as a substitute for tumor tissue in detecting egfr mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. *Medicine (Baltimore)*. May 2015;94(21):e775. PMID 26020382
5. Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. Jan 2015;24(1):206-212. PMID 25339418
6. Sacher AG, Pawletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. *JAMA Oncol*. Apr 7 2016. PMID 27055085
7. Pailler E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. *J Clin Oncol*. Jun 20 2013;31(18):2273-2281. PMID 23669222
8. Pailler E, Auger N, Lindsay CR, et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. *Ann Oncol*. Jul 2015;26(7):1408-1415. PMID 25846554
9. Lyberopoulou A, Aravantinos G, Efsthopoulos EP, et al. Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. *PLoS One*. 2015;10(4):e0123902. PMID 25902072
10. Taberero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. *Lancet Oncol*. Aug 2015;16(8):937-948. PMID 26184520
11. Labgaa I, Villanueva A. Liquid biopsy in liver cancer. *Discov Med*. Apr 2015;19(105):263-273. PMID 25977189
12. Xu MJ, Dorsey JF, Amaravadi R, et al. Circulating tumor cells, DNA, and mRNA: potential for clinical utility in patients with melanoma. *Oncologist*. Jan 2016;21(1):84-94. PMID 26614709
13. Riva F, Dronov OI, Khomenko DI, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. *Mol Oncol*. Mar 2016;10(3):481-493. PMID 26856794
14. Schmidt H, Kulasinghe A, Perry C, et al. A liquid biopsy for head and neck cancers. *Expert Rev Mol Diagn*. Feb 2016;16(2):165-172. PMID 26631411
15. Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. *Clin Cancer Res*. Oct 15 2012;18(20):5701-5710. PMID 22908097
16. Zhao S, Liu Y, Zhang Q, et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. *Breast Cancer Res Treat*. 2011;130(3):809-816.
17. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. *N Engl J Med*. 2004;351(8-Jan):781-791.

18. Nole F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. *Ann Oncol.* 2008;19(5):891-897.
19. Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. *Ann Oncol.* 2012;23(3-Jan):618-624.
20. Ma X, Xiao Z, Li X, et al. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. *Tumour Biol.* Feb 22 2014. PMID 24563278
21. Wang FB, Yang XQ, Yang S, et al. A higher number of circulating tumor cells in peripheral blood indicates poor prognosis in prostate cancer patients-a meta-analysis. *Asian Pac J Cancer Prev.* 2011;12(10):2629-2635.
22. de Bono J., Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2008;14(19):6302-6309.
23. Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. *BMC Cancer.* 2015;15:202. PMID 25880692
24. Groot Koerkamp B, Rahbari NN, Buchler MW, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. *Ann Surg Oncol.* Mar 2 2013;20(7):2156-2165. PMID 23456317
25. Sanguedolce F, Cormio A, Bufo P, et al. Molecular markers in bladder cancer: Novel research frontiers. *Crit Rev Clin Lab Sci.* 2015;52(5):242-255. PMID 26053693
26. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol.* 2008;26(19):3213-3221.
27. Seeberg LT, Waage A, Brunborg C, et al. Circulating Tumor Cells in Patients With Colorectal Liver Metastasis Predict Impaired Survival. *Ann Surg.* Feb 6 2014. PMID 24509211
28. Bork U, Rahbari NN, Scholch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. *Br J Cancer.* Apr 14 2015;112(8):1306-1313. PMID 25867263
29. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. *J Clin Oncol.* 2011;29(12):1556-1563.
30. Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. *J Thorac Oncol.* 2012;7(3):512-519.
31. Hirose T, Murata Y, Oki Y, et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. *Oncol Res.* 2012;20(2-3):131-137. PMID 23193919
32. Ma XL, Xiao ZL, Liu L, et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. *Asian Pac J Cancer Prev.* 2012;13(4):1137-1144. PMID 22799295
33. Guzzo TJ, McNeil BK, Bivalacqua TJ, et al. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. *Urol Oncol.* 2012;30(1):44-48.
34. Rink M, Chun FK, Minner S, et al. Detection of circulating tumor cells in peripheral blood of patients with advanced non-metastatic bladder cancer. *BJU Intl.* 2011;107(10):1668-1675.
35. Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. *Int J Cancer.* Mar 6 2014. PMID 24599551
36. de Albuquerque A., Kubisch I, Breier G, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. *Oncology.* 2012;82(1):3-10.
37. Okabe H, Tsunoda S, Hosogi H, et al. Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer. *Ann Surg Oncol.* Mar 17 2015. PMID 25777087
38. Schulze K, Gasch C, Staufer K, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. *Int J Cancer.* Nov 2013;133(9):2165-2171. PMID 23616258
39. Nichols AC, Lowes LE, Szeto CC, et al. Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. *Head Neck.* Oct 2012;34(10):1440-1444. PMID 22076949
40. Khoja L, Lorigan P, Zhou C, et al. Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. *J Invest Dermatol.* Dec 6 2013;133(6):1582-1590. PMID 23223143
41. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *Int J Cancer.* Mar 1 2014;134(5):1207-1213. PMID 23934701
42. Zhang J, Wang HT, Li BG. Prognostic significance of circulating tumor cells in small--cell lung cancer patients: a meta-analysis. *Asian Pac J Cancer Prev.* 2014;15(19):8429-8433. PMID 25339041

43. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. *J Clin Oncol*. Nov 1 2014;32(31):3483-3489. PMID 24888818
44. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2016). 2016;  
[https://www.nccn.org/professionals/physician\\_gls/pdf/breast\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf). Accessed May, 2016.

## Endnotes

---

<sup>1</sup> Based on MPRM 2.04.141 and expert opinion.